Respiratory
Tozorakimab: A Promising Monoclonal Antibody to Reduce COPD Exacerbations
Tozorakimab, targeting interleukin-33, significantly reduces moderate to severe COPD exacerbations in former and current smokers despite standard inhaled therapy, offering a novel therapeutic approach with a favorable safety profile.
